Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Neumora Therapeutics, Inc. Common Stock

Brain diseases collectively represent one of the largest areas of unmet medical need, affecting upwards of 1.5 billion patients globally. Neumora was founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. Our goal is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients.

We’ve built a pipeline comprised of programs for neuropsychiatric disorders and neurodegenerative diseases, each targeting a novel mechanism of action where we can leverage our precision neuroscience approach. Our pipeline currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. 

Neumora is committed to addressing some of the most prevalent brain health disorders and transforming the standard of care for millions of patients living with brain diseases. Learn more about Neumora and career opportunities on our website below.

Mubadala Capital Ventures

Invus

Abu Dhabi Growth Fund

Altitude Life Science Ventures

Amgen

EXOR N.V.

ARCH Venture Partners

Newpath Management

Polaris Partners

F-Prime Capital

Neumora

We are delighted to welcome Kaya Pai Panandiker as Chief Commercial Officer. Kaya brings to Neumora extensive commercial strategy and execution expertise, having led the launches of multiple neuropsychiatry products throughout her career. Read more: https://lnkd.in/ex-Zr2JP

Each year, our CEO Excellence Awards celebrate individuals or cross functional teams who demonstrate our values every day by achieving the extraordinary, creating value and doing what is right. We were thrilled to recognize our 2023 winners, Karla Zeitz, Jason Morton, Partha Mudipalli, Ph.D., Hong Ji, Santnu P., Michael Eyre, Heather Stemper, Palwasha T., Leanna Bui, Tash Barrow, Kelly Voong and Anh Le Vynh, for their outstanding contributions to Neumora. Thank you for your unwavering dedication to this work!

We’ve had a great week connecting with #JPM24 attendees! #ICYMI, check out CEO Henry Gosebruch’s podium presentation, outlining the exciting year ahead and our industry-leading pipeline. We look forward to continuing to pioneer a new era in brain disease and lead innovation in brain health throughout 2024. https://lnkd.in/eRFzBnEY

Neumora was founded to improve the lives of people living with brain diseases. To do that, we’ve built an industry-leading pipeline comprised of programs for neuropsychiatric disorders and neurodegenerative diseases, each targeting a novel mechanism of action. Learn more about our pipeline below. #JPM24

We are heading to San Francisco next week for #JPM24! CEO Henry Gosebruch will present on Monday, January 8 at 11:15AM PT. Learn more below. https://lnkd.in/ePiU73Zx

We are headed into this holiday season filled with gratitude for those around us. Wishing you the happiest of holidays from all of us at Neumora!

A recent NAMI study found that 64% of people with a mental illness said holidays make their conditions worse. It's important to put yourself first and prioritize your well-being, especially during the holiday season. We're sharing some of our favorite tips from NAMI and The Jed Foundation (JED) on how to reduce stress and maintain good #mentalhealth in the coming weeks. In an emergency, dial 988 to reach the suicide and crisis lifeline.

We are pleased to welcome Jason G. Duncan to Neumora as Chief Legal Officer. Jason's decades of legal, compliance, development and operations experience will be invaluable to our team as we continue to progress our pipeline. Read more: https://lnkd.in/eUdk_Gkr

We had a great time in Tampa at #ACNP2023, where Dr. Sanjay Mathew presented data from our #MDD program. It was great to connect with so many neuropsych thought leaders!

Today we announced IND clearance and the initiation of a Phase 1 study for NMRA-266, our M4 positive allosteric modulator. Read more here. https://lnkd.in/e_Vz_cjb

	Dec '20	Dec '21	Dec '22	Dec '23
revenue
cost of revenue				668K -
gross profit				-668K -
selling and marketing expenses
general and administrative expenses	8.39M -	24.55M 192.50%	31.12M 26.78%
selling general and administrative expenses	8.39M -	24.55M 192.50%	31.12M 26.78%	44.81M 43.98%
research and development expenses	87.13M -	212.78M 144.22%	104.75M 50.77%	142.72M 36.25%
other expenses	-3.75M -	11K 100.29%	405K 3,581.82%
cost and expenses	95.52M -	237.32M 148.46%	135.87M 42.75%	188.19M 38.51%
operating expenses	95.52M -	237.32M 148.46%	135.87M 42.75%	187.53M 38.02%
interest expense
ebitda	-95.41M -	-236.78M 148.17%	-135.28M 42.87%	-187.53M 38.62%
operating income	-95.52M -	-237.32M 148.46%	-135.87M 42.75%	-188.19M 38.51%
depreciation and amortization	105K -	538K 412.38%	594K 10.41%	668K 12.46%
total other income expenses net	-3.75M -	11K 100.29%	405K 3,581.82%	-47.46M 11,819.26%
income before tax	-99.27M -	-237.31M 139.05%	-130.90M 44.84%	-235.66M 80.02%
income tax expense			-4.56M -	268K 105.88%
net income	-99.27M -	-237.31M 139.05%	-130.90M 44.84%	-235.93M 80.23%
weighted average shs out	151.95M -	151.95M 0%	151.95M 0%	158.83M 4.53%
weighted average shs out dil	151.95M -	151.95M 0%	151.95M 0%	158.83M 4.53%
eps	-0.65 -	-1.56 140%	-0.86 44.87%	-1.49 73.26%
epsdiluted	-0.65 -	-1.56 140%	-0.86 44.87%	-1.49 73.26%

COM:NEUMORATX

Neumora Therapeutics, Inc.

Last Close

9.69

22/11 21:00

Market Cap

1.72B

Beta: -

Volume Today

490.17K

Avg: -

Preview